This study reports mitochondrial dysfunction contributing to MSH2-deficient endometrial cancer development, identifying a noncanonical pathway for MSH2 deficient carcinogenesis which imparts vulnerability to metabolic targeting. Here, MSH2 is linked to endometrial cancer.